Compare Amgen, Inc. (AMGN) vs DENTSPLY SIRONA Inc (XRAY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs DENTSPLY SIRONA Inc — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while DENTSPLY SIRONA Inc trades at $12.26 (market cap $2.46B). The key difference: Amgen, Inc. is far larger — about 79.7× DENTSPLY SIRONA Inc's market cap, and DENTSPLY SIRONA Inc pays the higher dividend (5.04%). Which is the better fit depends on your goals.
| AMGN | XRAY | |
|---|---|---|
Market Cap | $196.12B | $2.46B |
Sector | Health | Health |
52-Week High | $388.16 | $16.85 |
52-Week Low | $271.18 | $9.64 |
Enterprise Value | $241.41B | $4.60B |
Dividend Yield | 2.77% | 5.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Dentsply Sirona (XRAY) trades at $12.26, up 3.11% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $598M in 2025, with negative profit margins and declining revenue trends. Recent news highlights distribution expansion and new AI product launches, while earnings have missed estimates for three consecutive quarters.
The outlook remains challenging with persistent losses and high debt levels, though analyst consensus suggests moderate upside to the $12.50 price target. Key risks include margin pressure and soft European demand, while potential catalysts include digital dentistry adoption and cost management under new CFO leadership.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About DENTSPLY SIRONA Inc
Dentsply Sirona Inc is a global manufacturer and distributor of dental supplies and equipment. The company's operating segments include Technologies & Equipment, which is responsible for the design, manufacture, sales, and distribution of products including dental implants, CAD/CAM systems, orthodontic clear aligner products, imaging systems, treatment centers, instruments, as well as certain healthcare device products, primarily catheters
Read more on XRAY →
